"It's really a pity for Taiwan," he says, explaining that Myozyme was originally licensed to Synpac of the UK. However, after the first phase of human trials, Synpac decided not to continue making investments, and transferred its license to Genzyme, relinquishing the opportunity to make a name for itself and win markets just when these achievements were within reach.
「我很替台灣感到可惜，」陳垣崇說，起初 Myozyme 是授權給和信集團在英國投資的藥廠 Synpac，但做完第一階段人體實驗後，該藥廠決定不繼續投資而轉讓給美國的 Genzyme 藥廠，把已經成功在望的聲名與市場拱手讓人。